A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer

被引：0

作者：

Reckamp, Karen L. ^{[1
]}

Akerley, Wallace ^{[2
]}

Edelman, Martin J. ^{[3
]}

Halmos, Balazs ^{[4
]}

He, Kai ^{[5
,6
]}

Johnson, Melissa ^{[7
]}

Mudad, Raja ^{[8
,9
]}

Neal, Joel W. ^{[10
]}

Owonikoko, Taofeek K. ^{[11
]}

Patel, Jyoti D. ^{[12
]}

Patel, Sandip P. ^{[13
]}

Riess, Jonathan W. ^{[14
]}

Sacher, Adrian G. ^{[15
]}

Turcotte, Simon ^{[16
]}

Villaruz, Liza C. ^{[17
]}

Zauderer, Marjorie G. ^{[18
]}

Farsaci, Benedetto ^{[19
]}

Hasan, Aisha ^{[19
]}

Patel, Roma ^{[20
]}

Wu, Yuehui ^{[19
]}

Chisamore, Michael ^{[21
]}

Lam, Vincent ^{[22
]}

机构：

[1] City Hope Comprehens Canc Ctr, Duarte, CA USA

[2] Huntsman Canc Inst, Salt Lake City, UT USA

[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[4] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[5] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[6] James Canc Hosp, Columbus, OH USA

[7] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[8] Univ Miami, Miller Sch Med, Dept Med, Div Oncol, Miami, FL 33136 USA

[9] Sylvester Comprehens Canc Ctr, Miami, FL USA

[10] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Univ Chicago, Chicago, IL 60637 USA

[13] UC San Diego Moores Canc Ctr, San Diego, CA USA

[14] UC Davis Comprehens Canc Ctr, Div Hematol Oncol, Sacramento, CA USA

[15] Princess Margaret Canc Ctr, Toronto, ON, Canada

[16] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[17] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[18] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[19] GSK, Philadelphia, PA USA

[20] GSK, Uxbridge, Middx, England

[21] Merck & Co Inc, N Wales, PA USA

[22] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT225

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT225

引用

页数：3

共 34 条

[31] A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
Thomas, M.
Sadjadian, P.
Kollmeier, J.
Lowe, J.
Mattson, P.
Trout, J. R.
Gargano, M.
Patchen, M. L.
Walsh, R.
Beliveau, M.
Marier, J. F.
Bose, N.
Gorden, K.
Schneller, F., III
INVESTIGATIONAL NEW DRUGS, 2017, 35 (03) : 345 - 358
[32] Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03
Planchard, David
Brahmer, Julie R.
Yang, James C.
Chen, Yuh-Min
Lee, Kang-Yun
Suksombooncharoen, Thatthan
Viglianti, Natasha
Gustavson, Mark
Ragone, Alejandra
Hernandez, Amaya Gasco
CANCER RESEARCH, 2022, 82 (12)
[33] A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC).
Planchard, David
Shtivelband, Mikhail
Shi, Kelvin
Ibrahim, Ramy
Ballas, Marc
Soria, Jean-Charles
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[34] AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate
Lillian, S.
De Bono, J.
Higano, C.
Shapiro, G.
Brugger, W.
Mitchell, P.
Colebrook, S.
Klinowska, T.
Barry, S.
Dean, E.
Martin-Mills, J.
Wisinski, K.
Moorthy, G.
Mills, J.
Cruzalegui, F.
Tolaney, S.
Lang, J.
Luken, M. Jose De Miguel
Kunar, R.
Chatta, G.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S19 - S19

← 1 2 3 4 →